|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,1





* Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;
Department of Cellular and Molecular Medicine,
Department of Chemical Engineering, and
Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada; and
¶ Department of Vision, Ottawa Health Research Institute, Ottawa, Ontario, Canada
1 Correspondence: Erik J. Suuronen, Division of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada. E-mail: esuuronen{at}ottawaheart.ca
Circulating progenitor cells home to and engraft to sites of ischemia, mediated in part by the adhesion molecule L-selectin; however, accumulation in tissues such as the heart is low. In this study, an acellular collagen-based matrix containing sialyl LewisX (sLeX), which binds L-selectin, was developed in order to enhance the endogenous progenitor cell therapeutic response. Its effect on progenitor cells and angiogenesis were assessed in vitro and using a hindlimb ischemia model with rats. In culture, the sLeX-collagen matrix recruited more CD133+CD34+L-selectin+ cells than collagen-only matrix, with adhesion mediated by L-selectin binding. Increased angiogenic/chemotactic cytokine production and improved resistance to apoptosis appeared in cells cultured on sLeX-collagen matrix. In vivo, mobilization of endogenous circulating progenitor cells was increased, and greater recruitment of these and systemically injected human peripheral blood CXCR4+L-selectin+ cells to sLeX-collagen treated limbs was observed compared to collagen-only. This condition was associated with differences in angiogenic/chemotactic cytokine levels, with greater arteriole density and increased perfusion in sLeX-collagen treated hindlimbs. With these factors taken together, we demonstrated that an acellular matrix-bound ligand approach can enhance the mobilization, recruitment, and therapeutic effects of endogenous and/or transplanted progenitor cells, possibly through paracrine and antiapoptotic mechanisms, and could be used to improve cell-based regenerative therapies.—Suuronen, E. J., Zhang, P., Kuraitis, D., Cao, X., Melhuish, A., McKee, D., Li, F., Mesana, T. G., Veinot, J. P., Ruel, M. An acellular matrix-bound ligand enhances the mobilization, recruitment and therapeutic effects of circulating progenitor cells in a hindlimb ischemia model.
Key Words: tissue engineering stem cells angiogenesis cell homing paracrine effects apoptosis
This article has been cited by other articles:
![]() |
E. Chavakis, M. Koyanagi, and S. Dimmeler Enhancing the Outcome of Cell Therapy for Cardiac Repair: Progress From Bench to Bedside and Back Circulation, January 19, 2010; 121(2): 325 - 335. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |